Thermo Fisher Scientific (TMO)
NYSE:TMO
Want to see TMO full AI Analyst Report?
TMO Stock Chart & Stats
$526.60
$0.83(0.15%)
At close: 4:00 PM EST
$526.60
$0.83(0.15%)
Day’s Range― - ―
52-Week Range$385.46 - $643.99
Previous CloseN/A
Volume471.20K
Average Volume (3M)2.43M
Market Cap
$175.64B
Enterprise Value$211.48B
Total Cash (Recent Filing)$3.26B
Total Debt (Recent Filing)$43.16B
Price to Earnings (P/E)25.0
Beta0.72
Next Earnings
Jul 29, 2026EPS Estimate
5.72Next Dividend Ex-DateN/A
Dividend Yield0.3%
Share Statistics
EPS (TTM)18.22
Shares Outstanding371,621,460
10 Day Avg. Volume2,020,144
30 Day Avg. Volume2,425,259
Financial Highlights & Ratios
PEG Ratio4.51
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue4.68
Enterprise Value/Gross Profit11.87
Enterprise Value/Ebitda18.95
Forecast
1Y Price Target
$594.94Price Target Upside12.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)24.86
Revenue Forecast (FY)$47.77B
Bulls Say, Bears Say
Bulls Say
Cash GenerationThermo Fisher's persistently strong free cash flow (~$6.7B TTM) and high FCF-to-net-income (~80%) provide durable internal funding for R&D, capex, dividends, buybacks and M&A. Reliable cash conversion supports strategic flexibility and ability to service debt over a multi-year horizon.
Recurring ConsumablesA large portion of revenue comes from consumables, reagents and service attachments that create predictable, repeat purchasing patterns. This installed-base driven model produces steady revenue streams and margin resilience, reducing sensitivity to single instrument cycles over months to years.
Strategic M&A (Clario)The Clario acquisition adds digital endpoint data and analytics to Thermo Fisher's biopharma services, expanding higher-growth, higher-margin offerings. Management expects accretion, synergies and enhanced drug‑development value prop, strengthening long-term differentiation with pharma customers.
Bears Say
Elevated LeverageMaterial absolute debt and increased leverage following M&A limit financial flexibility and amplify interest‑rate and refinancing risks. Sustained high leverage constrains capital allocation choices and raises the priority of cash generation for deleveraging rather than growth investments over the medium term.
Muted Organic GrowthA multi-year trend of low organic growth reduces operating leverage and makes long‑term margin expansion harder to sustain. When top-line momentum is modest, returns on incremental investment fall and reliance on acquisitions or pricing mix to hit targets increases strategic execution risk.
Cyclical Instrument DemandAcademic, government and China weakness drove softer Analytical Instruments revenue and a sharp margin decline. The cyclical nature and geographic concentration of instrument demand makes near-term recovery uncertain and can press segment profitability and installed‑base driven consumable follow‑on over quarters.
Thermo Fisher News
TMO FAQ
What was Thermo Fisher Scientific’s price range in the past 12 months?
Thermo Fisher Scientific lowest stock price was $385.46 and its highest was $643.99 in the past 12 months.
What is Thermo Fisher Scientific’s market cap?
Thermo Fisher Scientific’s market cap is $175.64B.
When is Thermo Fisher Scientific’s upcoming earnings report date?
Thermo Fisher Scientific’s upcoming earnings report date is Jul 29, 2026 which is in 41 days.
How were Thermo Fisher Scientific’s earnings last quarter?
Thermo Fisher Scientific released its earnings results on Apr 23, 2026. The company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.248 by $0.192.
Is Thermo Fisher Scientific overvalued?
According to Wall Street analysts Thermo Fisher Scientific’s price is currently Undervalued.
Does Thermo Fisher Scientific pay dividends?
Thermo Fisher Scientific pays a Quarterly dividend of $0.47 which represents an annual dividend yield of 0.3%. See more information on Thermo Fisher Scientific dividends here
What is Thermo Fisher Scientific’s EPS estimate?
Thermo Fisher Scientific’s EPS estimate is 5.72.
How many shares outstanding does Thermo Fisher Scientific have?
Thermo Fisher Scientific has 371,621,460 shares outstanding.
What happened to Thermo Fisher Scientific’s price movement after its last earnings report?
Thermo Fisher Scientific reported an EPS of $5.44 in its last earnings report, beating expectations of $5.248. Following the earnings report the stock price went down -9.199%.
Which hedge fund is a major shareholder of Thermo Fisher Scientific?
Currently, no hedge funds are holding shares in TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$594.94 (12.98% Upside)
$594.94 (12.98% Upside)
Blogger Sentiment
Bullish
TMO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.73%
12-Months-Change
Fundamentals
Return on Equity
13.26%
Trailing 12-Months
Asset Growth
14.38%
Trailing 12-Months
Company Description
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
TMO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid operational execution and strategic progress: Thermo Fisher delivered a strong quarter with mid-single-digit reported revenue growth, EPS growth, meaningful product launches, accretive M&A (Clario) and raised full-year guidance. Positives included strong Life Sciences Solutions and Laboratory Products performance, robust cash generation, and continued shareholder returns. Offsetting risks highlighted were low organic growth in Q1, weakness in Analytical Instruments and certain diagnostics markets (notably academic/government and China), tariff/FX headwinds, elevated leverage following the acquisition, and an inflation uncertainty placeholder. Overall, the constructive financial results and upward guidance outweighed the near-term headwinds and uncertainties.View all TMO earnings summariesTMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
TMO Stock 12 Month Forecast
Average Price Target
$594.94
▲(12.98% Upside)
Technical Analysis
Ownership Overview
0.13% Insiders
24.26% Mutual Funds
26.81% Other Institutional Investors
29.04% Public Companies and Individual Investors